Zydus Lifesciences (previously called Cadila Healthcare) said that it has secured final approval from the US Food and Drug Administration (FDA) to market Bortezomib for Injection, 3.5 mg/vial, Single-Dose Vial.

Bortezomib for Injection is the generic of Velcade (bortezomib), which has a market size of $1.17bn as per IQVIA MAT March 2022.

It is used for the treatment of some forms of cancer that include multiple myeloma and mantle cell lymphoma.

The drug works by either slowing or stopping the growth of cancer cells.

Bortezomib for Injection will be manufactured at Zydus Hospira.

Zydus Lifesciences currently has 331 approvals and till now has submitted more than 400 abbreviated new drug applications (ANDAs) since the start of filing process in FY 2003-04.

  bortezomib, Bortezomib for Injection, Cadila Healthcare, cancer, Lymphoma, mantle cell lymphoma, Multiple myeloma, US Food and Drug Administration, Velcade, Zydus, Zydus Hospira, Zydus Lifesciences